Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| NCT ID | NCT02164006 |
| Title | Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | TG Therapeutics, Inc. |
| Indications | |
| Therapies | |
| Age Groups: | adult |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| TG Therapeutics Investigational Trial Site | Duarte | California | 91010 | United States | Details | |
| TG Therapeutics Investigational Trial Site | San Diego | California | 92093 | United States | Details | |
| TG Therapeutics Investigational Trial Site | Sarasota | Florida | 34232 | United States | Details | |
| TG Therapeutics Investigational Trial Site | Detroit | Michigan | 48201 | United States | Details |